Antibiotic Therapy for Infectious Diseases

Launched by SHANDONG UNIVERSITY · Jun 23, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called tigecycline, which is a strong antibiotic that doctors use as a last option for treating serious infections caused by bacteria that don't respond to other antibiotics. The main goal of this study is to find out how effective and safe tigecycline is for patients who are critically ill and have severe infections. Researchers will look at how the drug works in the body and gather detailed information to better understand its effects.

To be part of this study, participants need to be hospitalized men or non-pregnant women aged 18 and older who are being treated with tigecycline for severe infections. However, people with serious liver problems, those who are allergic to similar medications, or who are currently involved in other clinical trials cannot join. If eligible, participants can expect close monitoring while receiving the medication, and their experiences will help improve our understanding of tigecycline for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • critically ill hospitalized males or nonpregnant females aged 18 years with severe infections which the treating clinician was treating with tigecycline
• Exclusion Criteria:
• • 1. severe liver dis- eases (e.g., Child-Pugh score C);
• • 2. patients allergic to tetracycline and tigecycline;
• • 3. those who have participated in other clinical trials, or those who are considered unsuitable by researchers;
• • 4. pregnant women and lactating women.